Vivoryon Therapeutics N.V. announced the appointment of Anne Doering as Chief Financial Officer (CFO), leveraging Ms. Doering?s deep capital markets experience and enabling a smooth management transition as she succeeds Florian Schmid on March 1, 2024.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.762 EUR | -4.75% | +33.68% | -90.64% |
Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-90.64% | 22.26M | |
+1.51% | 42.75B | |
+48.26% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Vivoryon Therapeutics N.V. Announces Executive Changes